Dual antithrombotic treatment in chronic coronary syndrome: European Society of Cardiology criteria vs. CHADS-P2A2RC score

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

8 Citationer (Scopus)

Abstract

Aims According to the 2019 European Society of Cardiology (ESC) guidelines on chronic coronary syndromes (CCS), adding a P2Y12 inhibitor or rivaroxaban to aspirin should be considered in high-risk patients. We estimated the proportion of patients eligible for treatment with the ESC criteria and examined if a recently validated risk score (CHADS-P(2)A(2)RC) could improve risk prediction. Methods and results We included 61 338 CCS patients undergoing first-time coronary angiography in Western Denmark (2003-16) and classified them according to the ESC criteria and the CHADS-P(2)A(2)RC score. The ESC criteria identified 33.9% as high risk, 53.3% as moderate risk, and 12.8% as low risk. The CHADS-P(2)A(2)RC score identified 24.9% as high risk (>= 4 points), 48.1% as moderate risk (2-3 points), and 27.0% as low risk (

OriginalsprogEngelsk
TidsskriftEuropean Heart Journal
Vol/bind43
Nummer10
Sider (fra-til)996-1004
Antal sider10
ISSN0195-668X
DOI
StatusUdgivet - mar. 2022

Fingeraftryk

Dyk ned i forskningsemnerne om 'Dual antithrombotic treatment in chronic coronary syndrome: European Society of Cardiology criteria vs. CHADS-P2A2RC score'. Sammen danner de et unikt fingeraftryk.

Citationsformater